PERKINELMER INC (PKI) Stock Overview
USA - NYSE:PKI - US7140461093 - Common Stock
PKI Key Statistics, Chart & Performance
The current stock price of PKI is 115.24 USD. In the past month the price decreased by -15.23%. In the past year, price decreased by -21.46%.
PKI Latest News, Press Relases and Analysis
PKI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.17 | 212.89B | ||
| DHR | DANAHER CORP | 28.67 | 158.25B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 144.36 | 47.09B | ||
| A | AGILENT TECHNOLOGIES INC | 26.9 | 41.56B | ||
| IQV | IQVIA HOLDINGS INC | 18.96 | 36.96B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.71 | 29.25B | ||
| WAT | WATERS CORP | 28.76 | 20.94B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.63 | 20.65B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.71 | 16.76B | ||
| TEM | TEMPUS AI INC | N/A | 15.91B | ||
| ILMN | ILLUMINA INC | 24.12 | 15.42B | ||
| ICLR | ICON PLC | 13.8 | 14.16B |
Related stock screener links
About PKI
Company Profile
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. The company is headquartered in Waltham, Massachusetts and currently employs 16,700 full-time employees. The firm operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. Its products and services for Discovery & Analytical Solutions applications include The Opera Phenix Plus high-content screening system, The Operetta CLS high-content analysis system, The MuviCyte live-cell imaging system, and The Signals Image Artist. Its products and services for Diagnostics applications include The DELFIA Xpress screening platform, The Specimen Gate informatics data management solution and The DELFIA Xpress sFlt-1 kit.
Company Info
PERKINELMER INC
940 Winter Street
Waltham MASSACHUSETTS 02451 US
CEO: Prahlad Singh
Employees: 16700
Phone: 17816635776.0
PERKINELMER INC / PKI FAQ
What does PERKINELMER INC do?
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. The company is headquartered in Waltham, Massachusetts and currently employs 16,700 full-time employees. The firm operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. Its products and services for Discovery & Analytical Solutions applications include The Opera Phenix Plus high-content screening system, The Operetta CLS high-content analysis system, The MuviCyte live-cell imaging system, and The Signals Image Artist. Its products and services for Diagnostics applications include The DELFIA Xpress screening platform, The Specimen Gate informatics data management solution and The DELFIA Xpress sFlt-1 kit.
What is the current price of PKI stock?
The current stock price of PKI is 115.24 USD. The price decreased by -0.91% in the last trading session.
What is the dividend status of PERKINELMER INC?
PKI does not pay a dividend.
What is the ChartMill technical and fundamental rating of PKI stock?
PKI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Should I buy PKI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PKI.
Can you provide the upcoming earnings date for PERKINELMER INC?
PERKINELMER INC (PKI) will report earnings on 2023-07-31, before the market open.
PKI Technical Analysis
PKI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PKI. While PKI seems to be doing ok healthwise, there are quite some concerns on its profitability.
PKI Financial Highlights
Over the last trailing twelve months PKI reported a non-GAAP Earnings per Share(EPS) of 7.94. The EPS decreased by -30.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.32% | ||
| ROA | 5.28% | ||
| ROE | 10.11% | ||
| Debt/Equity | 0.53 |
PKI Forecast & Estimates
20 analysts have analysed PKI and the average price target is 159.39 USD. This implies a price increase of 38.31% is expected in the next year compared to the current price of 115.24.
For the next year, analysts expect an EPS growth of -34.36% and a revenue growth -31.32% for PKI